Kobayashi Minoru, Morita Tatsuo, Chun Nicole A L, Matsui Aya, Takahashi Masafumi, Murakami Takashi
Department of Urology, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Tumour Biol. 2012 Apr;33(2):551-9. doi: 10.1007/s13277-011-0300-4. Epub 2012 Jan 5.
There has been little information about metastatic behavior of renal cell carcinoma (RCC) cells because human cancers metastasize only rarely in immunodeficient mice. Moreover, it is difficult to know the effect of host immunity on RCC metastasis due to lack of such RCC cells as transplantable in not only xenograft models but also counterparts with intact immunity. Therefore, we scrutinized in vivo metastasis of RCC cells to seek for the optimal preclinical model to study metastatic behavior. The luciferase-expressing three representative human RCC cell lines (Caki-1, A498, and 786-O) and rat ACI-RCC cell which were established in our laboratory were transplanted into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice or immunocompetent ACI rats by intracardiac injection as well as orthotopic inoculation. Metastasis was monitored using a bioluminescent imaging technique. Metastasis was rare in the three human RCC cells even when they were directly disseminated into systemic circulation under the condition least susceptible to host immune attack in NOD/SCID mice. In contrast, ACI-RCC cells spontaneously metastasized to pulmonary tissue from orthotopic tumor sites and systemically spread via intracardiac route. Metastases were more extensive when the cells were inoculated into an immunodeficient host, implying suppressive effect of host immunity on colonization of RCC cells. These results suggest that the representative human RCC cells are not adequate resource to study metastasis but that the luciferase-labeled ACI-RCC cell characterized by its luminescent stability, enhanced tumorigenicity, and widespread metastatic potential provides a useful in vivo model for preclinical assessment of cancer progression and potential therapies against RCC.
关于肾细胞癌(RCC)细胞的转移行为,目前所知甚少,因为人类癌症在免疫缺陷小鼠中很少发生转移。此外,由于缺乏不仅可移植到异种移植模型而且可移植到具有完整免疫力的对应模型中的RCC细胞,因此很难了解宿主免疫对RCC转移的影响。因此,我们仔细研究了RCC细胞的体内转移情况,以寻找研究转移行为的最佳临床前模型。将我们实验室建立的三种代表性的表达荧光素酶的人RCC细胞系(Caki-1、A498和786-O)以及大鼠ACI-RCC细胞通过心内注射和原位接种移植到非肥胖糖尿病/严重联合免疫缺陷(NOD/SCID)小鼠或具有免疫活性的ACI大鼠体内。使用生物发光成像技术监测转移情况。即使将这三种人RCC细胞直接注入NOD/SCID小鼠中最不易受到宿主免疫攻击的全身循环中,转移也很少见。相比之下,ACI-RCC细胞从原位肿瘤部位自发转移到肺组织,并通过心内途径全身扩散。当将细胞接种到免疫缺陷宿主中时,转移更为广泛,这意味着宿主免疫对RCC细胞定植具有抑制作用。这些结果表明,代表性的人RCC细胞不是研究转移的合适资源,但荧光素酶标记的ACI-RCC细胞具有发光稳定性、增强的致瘤性和广泛的转移潜力,为癌症进展的临床前评估和针对RCC的潜在治疗提供了一种有用的体内模型。